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Introduction
Cardiac sarcoidosis is associated with sudden arrhythmic
death, conduction abnormalities and heart failure. Occult
disease is frequently found at autopsy although its signif-
icance remains unclear. Late gadolinium enhancement
(LGE) on cardiac magnetic resonance (CMR) imaging per-
mits detection of granulomatous cardiac infiltration and
myocardial fibrosis.
Purpose
We sought to establish whether CMR diagnosis of cardiac
sarcoidosis correlates with clinical outcome in this com-
plex disease.
Methods
96 consecutive patients with sarcoidosis were referred to
our centre for CMR between 2002 and 2007 (46 M, 50 F;
mean age 57 years). Outcomes in two cohorts distin-
guished by evidence of LGE were retrospectively assessed
(mean follow-up 3.5 years). Left ventricular (LV) vol-
umes, ejection fraction (EF) and mass were evaluated
using semi-automated analysis software and indexed to
body surface area. Continuous variables were reported as
mean ± standard deviation; groups (based on the presence
or absence of LGE) were compared using a t-test or
Fisher's exact test.
Results
LGE was observed in 31 out of 96 (32%) patients. No sig-
nificant difference was seen in all-cause death or hospital-
isation for a cardiovascular event between the LGE+ and
LGE- cohort. The LGE+ cohort had a significantly greater
rate of ICD implantation (7 vs 1, p < 0.0005) and appro-
priate ICD discharge (4 vs 0, p < 0.005). Notably, only
four patients had right ventricular LGE+; all required defi-
brillator (ICD) implantation and sustained appropriate
ICD discharge. There was no difference in other secondary
outcomes such as pre-ICD implantation sustained ven-
tricular tachycardia, pacemaker implantation rate or esca-
lation of heart failure therapy. Amongst LGE+ individuals,
there was a significant reduction in biventricular EF (LVEF
50 ± 13.0% vs. 64 ± 10%, p < 0.05; RVEF 49 ± 13 vs. 58 ±
9%, p < 0.05). RVEDV was also significantly greater (173
± 14 vs.137 ± 5 mls, p < 0.0065), although not LVEDV
(105 ± 5.9 vs. 132 ± 7.9 mls, p < 0.0066). The distribution
of LGE did not appear to correlate with outcome. The two
groups did not differ in the incidence of biopsy-proven
sarcoidosis (48/96 cases), pre-referral cardiac symptoms
or duration of follow-up. Within this cohort, only five
patients had STIR imaging clearly suggestive of active car-
diac sarcoidosis.
Conclusion
In this cohort, presence of cardiac LGE in sarcoidosis is
associated with increased ICD implantation and appro-
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priate discharge but not worse mortality or hospitaliza-
tion outcome, despite an associated biventricular
reduction in ejection fraction. RV LGE may predict a
requirement for ICD implantation. Further prospective
research is needed to improve understanding of this com-
plex disease.Page 2 of 2
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